LY 303366. ECB.
D000077612:Anidulafungin; D000818:Animals; D000935:Antifungal Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy / Q000382:microbiology; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy / Q000382:microbiology; D015507:Drugs, Investigational / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D054714:Echinocandins; D005260:Female; D005658:Fungi / Q000187:drug effects; D006801:Humans; D008297:Male; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology; D010456:Peptides, Cyclic / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D016720:Pneumocystis Infections / Q000188:drug therapy; D051381:Rats
D000935:Antifungal Agents; D015507:Drugs, Investigational; D054714:Echinocandins; D010456:Peptides, Cyclic; D000077612:Anidulafungin